Equillium (EQ) Net Margin (2023 - 2024)
Equillium (EQ) posted quarterly Net Margin of 132.81% for Q4 2024, down 9412.0% year-over-year from 1.43% in Q1 2024, and down 230628.31% quarter-over-quarter from 0.06% in Q3 2024.
Equillium (EQ) Net Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported Net Margin for 2 consecutive years, with 132.81% the latest figure, recorded in Q4 2024.
- In Q4 2024, Net Margin fell 9412.0% year-over-year to 132.81%; the TTM figure through Sep 2025 stood at 670.67% (down 65796.0% YoY), while the FY2024 annual figure was 19.73%, up 2062.0% from the prior year.
- Net Margin eased to 132.81% in Q4 2024 per EQ's latest filing, from 0.06% in the prior quarter.
- Across five years, Net Margin topped out at 3.38% in Q2 2024 and bottomed at 132.81% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -132.81% |
| Sep 30, 2024 | -0.06% |
| Jun 30, 2024 | 3.38% |
| Mar 31, 2024 | -25.58% |
| Dec 31, 2023 | -38.69% |
| Sep 30, 2023 | -41.83% |
| Jun 30, 2023 | -36.64% |
| Mar 31, 2023 | -44.37% |